Skip to main content
. 2019 Apr 18;14(4):e0214604. doi: 10.1371/journal.pone.0214604

Fig 4. Survival probability based on joint effect of P53 and p16 expression.

Fig 4

A: Overall survival probability, P53+/P16+ VS. P53-/P16- (p = 0.000), P53+/P16+ vs. P53+/P16- (p = 0.008), P53+/P16- VS. P53-/P16+ (p = 0.049) and P53-/P16+ vs. P53-/P16- (p = 0.000) showed significant differences on overall survival. The worst outcome was seen in patients P53+/P16+ tumours.B: Disease free survival, P53+/P16+ VS. P53-/P16- (p = 0.000), P53+/P16+ vs. P53+/P16- (p = 0.017) and P53-/P16+ vs. P53-/P16- (p = 0.000) showed significant differences in DFS. The worst outcome was seen in patients with P53+/P16+ tumours.